ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...